For the other resistant Eμ-Myc lymphoma cell lines that had lost BAX expression, we examined whether BAX may be dysregulated at the pre-transcriptional or post-transcriptional levels by performing quantitative reverse-transcriptase PCR (qRT-PCR) for Bax mRNA following treatment of the cells with the TRP53-activating drug Nutlin-3a (Fig. 5B). This evidence concerns the gene BAX and lymphoma.